Proteon Therapeutics grabs $15.2M financing

Waltham, MA-based Proteon Therapeutics has raised $15.2 million in financing, the Boston Business Journal reports, citing SEC documents. The new funding is in exchange for equity and options and follows the company's initiation of a mid-stage trial of its lead drug, PRT-201, which the firm says aims to "improve the outcomes associated with the surgical creation of vascular accesses in chronic kidney disease patients undergoing hemodialysis." Novartis ($NVS) has an option to acquire Proteon after the small firm completes Phase II development of the drug. Report

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.